Conservative management of azoospermia following steroid abuse

Gazvani, M. R.; Buckett, William; Luckas, Murray; Aird, Ian; Hipkin, L. J.; Lewis‐Jones, D. I.

doi:10.1093/humrep/12.8.1706

Cited by 66 publications

(34 citation statements)

References 3 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…However, some users appear slow to recover HPG function and demonstrate prolonged hypogonadism, occasionally persisting more than a year after stopping AAS (Boyadjiev et al, 2000; Gazvani et al, 1997; Jarow and Lipshultz, 1990; Menon, 2003; Urhausen et al, 2003; van Breda et al, 2003). Hypogonadism may create a variety of adverse physiologic effects, including changes in body composition (loss of muscle and increased fat), loss of sexual drive and function, and fatigue (Almeida et al, 2004; Tan and Scally, 2009).…”

Section: The Androgenic Mechanismmentioning

confidence: 99%

Treatment of anabolic–androgenic steroid dependence: Emerging evidence and its implications

Kanayama

Brower

Wood

et al. 2010

Drug and Alcohol Dependence

108

View full text Add to dashboard Cite

Currently, few users of anabolic-androgenic steroids (AAS) seek substance-abuse treatment. But this picture may soon change substantially, because illicit AAS use did not become widespread until the 1980s, and consequently the older members of this AAS-using population-those who initiated AAS as youths in the 1980s-are only now reaching middle age. Members of this group, especially those who have developed AAS dependence, may therefore be entering the age of risk for cardiac and psychoneuroendocrine complications sufficient to motivate them for substance-abuse treatment. We suggest that this treatment should address at least three etiologic mechanisms by which AAS dependence might develop. First, individuals with body-image disorders such as "muscle dysmorphia" may become dependent on AAS for their anabolic effects; these body-image disorders may respond to psychological therapies or pharmacologic treatments. Second, AAS suppress the male hypothalamic-pituitary-gonadal axis via their androgenic effects, potentially causing hypogonadism during AAS withdrawal. Men experiencing prolonged dysphoric effects or frank major depression from hypogonadism may desire to resume AAS, thus contributing to AAS dependence. AAS-induced hypogonadism may require treatment with human chorionic gonadotropin or clomiphene to reactivate neuroendocrine function, and may necessitate antidepressant treatments in cases of depression inadequately responsive to endocrine therapies alone. Third, human and animal evidence indicates that AAS also possess hedonic effects, which likely promote dependence via mechanisms shared with classical addictive drugs, especially opioids. Indeed, the opioid antagonist naltrexone blocks AAS dependence in animals. By inference, pharmacological and psychosocial treatments for human opioid dependence might also benefit AASdependent individuals.

show abstract

Section: The Androgenic Mechanismmentioning

confidence: 99%

Treatment of anabolic–androgenic steroid dependence: Emerging evidence and its implications

Kanayama

Brower

Wood

et al. 2010

Drug and Alcohol Dependence

108

View full text Add to dashboard Cite

show abstract

“…This, in addition to individual predisposition, is most likely due to the depot effects of the huge steroid concentrations consumed (30,31). For example, after termination of nandrolone abuse metabolites could still be detected in urine after more than a year in some men (32).…”

Section: Suppression Of Spermatogenesismentioning

confidence: 99%

“…It also remains ethically questionable whether the consequences of hormone abuse should be counteracted by additional hormone treatment, when normal conditions can be reconstituted by strict termination of abuse and waiting for spontaneous recovery. Gonadotropin treatment may be justified only if no improvement has been observed within 24 months (30,46).…”

Section: Hypogonadism Induced By Anabolic Steroidsmentioning

confidence: 99%

MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions

Nieschlag

Vorona

2015

European Journal of Endocrinology

190

115

View full text Add to dashboard Cite

Anabolic androgenic steroids (AASs) are appearance and performance-enhancing drugs (APEDs) used in competitive athletics, in recreational sports, and by body-builders. The global lifetime prevalence of AASs abuse is 6.4% for males and 1.6% for women. Many AASs, often obtained from the internet and dubious sources, have not undergone proper testing and are consumed at extremely high doses and in irrational combinations, also along with other drugs. Controlled clinical trials investigating undesired side effects are lacking because ethical restrictions prevent exposing volunteers to potentially toxic regimens, obscuring a causal relationship between AASs abuse and possible sequelae. Because of the negative feedback in the regulation of the hypothalamic-pituitary-gonadal axis, in men AASs cause reversible suppression of spermatogenesis, testicular atrophy, infertility, and erectile dysfunction (anabolic steroid-induced hypogonadism). Should spermatogenesis not recover after AASs abuse, a pre-existing fertility disorder may have resurfaced. AASs frequently cause gynecomastia and acne. In women, AASs may disrupt ovarian function. Chronic strenuous physical activity leads to menstrual irregularities and, in severe cases, to the female athlete triad (low energy intake, menstrual disorders and low bone mass), making it difficult to disentangle the effects of sports and AASs. Acne, hirsutism and (irreversible) deepening of the voice are further consequences of AASs misuse. There is no evidence that AASs cause breast carcinoma. Detecting AASs misuse through the control network of the World Anti-Doping Agency (WADA) not only aims to guarantee fair conditions for athletes, but also to protect them from medical sequelae of AASs abuse.

show abstract

“…Al mismo tiempo la calidad seminal se ve afectada por múltiples factores, incluso si hubiera fecundación se podría producir un desarrollo anormal y pararse en estadíos avanzados del embrión. Así, haciendo un repaso a la bibliografía existente en las bases de datos encontramos estudios que relacionan parámetros anormales de calidad de semen y/o alteraciones en la fertilidad masculina, con la edad (5,6), peso/IMC (7), ocupación (5,6), disruptores endocrinos (8), drogas (9) y abuso de esteroides (10), entre otros.…”

Section: Introductionunclassified

Medicamentos como posible factor asociado a la infertilidad masculina

Martínez¹

2015

View full text Add to dashboard Cite

Revisión sistemática de las fichas técnicas (apartados 4.6 y 5.3) de los medicamentos más consumidos en España, según el Sistema Nacional de Salud, y revisión bibliográfica a través de PubMed, según un patrón de búsqueda estándar, con respecto a la influencia de éstos sobre la fertilidad masculina. Como resultado a esto nos encontramos con que de 29 principios activos estudiados, 15 no presentan datos referentes a la fertilidad masculina en su ficha técnica, para 18 no se recuperó información al respecto en la búsqueda en PubMed y 9 no disponen de material de información que provenga de ninguna de las dos fuentes de las que utilizamos. En 3 medicamentos los resultados de las dos fuentes coinciden y en 2 encontramos discrepancias. En 13 de los 29 fármacos estudiados se ha encontrado información de efectos adversos sobre la fertilidad masculina en alguna de las 2 fuentes de información revisadas. Se demuestra con esto una falta de información clara, concisa y contrastada. Medicines as a possible factor associated with male infertility ABSTRACTSystematic review of the technical specifications (4.6 and 5.3 paragraph) of the most frequently used drugs in Spain, from NHS, and the information provided by PubMed according to a standard search pattern with respect to their influence on male fertility. As a result of this we find that 15 of 29 active substances studied have no data about male fertility in their technical data sheets, 18 of this 29 have no data about male fertility from PubMed and 9 don't have any information coming from either source we used. 3 medicines have matching results from the two sources and other 2 found discrepancies. In 13 of the 29 drugs studied the information about adverse effects on male fertility was found in one of the two sources of information reviewed. It's demonstrated that it's necessary clear, concise and contrasted information. FC 23 PALABRAS CLAVEFertilidad masculina, espermatogénesis, medicamentos, efectos adversos KEYWORDSMale fertility, spermatogenesis, pharmaceutical preparations, adverse effects Financiación: Ninguna ajerna. Conflicto de intereses: La autora declara no existir conflicto de intereses en relación con el contenido del artículo. Cite este artículo como: Campos B. Medicamentos como posible factor asociado a la infertilidad masculina.

show abstract

Conservative management of azoospermia following steroid abuse

Cited by 66 publications

References 3 publications

Treatment of anabolic–androgenic steroid dependence: Emerging evidence and its implications

Treatment of anabolic–androgenic steroid dependence: Emerging evidence and its implications

MECHANISMS IN ENDOCRINOLOGY: Medical consequences of doping with anabolic androgenic steroids: effects on reproductive functions

Medicamentos como posible factor asociado a la infertilidad masculina

Contact Info

Product

Resources

About